The FDA has approved an updated indication for upadacitinib (Rinvoq; AbbVie) in inflammatory bowel disease (IBD), allowing its use in adults with moderately to severely active ulcerative colitis or ...

The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and ...

The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...

The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...

AbbVie recently announced positive topline results from its Phase 3b/4 SELECT-SWITCH trial, showing that Rinvoq (upadacitinib ...

NORTH CHICAGO, Ill., July 26, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg ...

AbbVie has received the U.S. Food and Drug Administration (FDA) approval for a supplemental new drug application (sNDA) that ...

– Late-breaking data from a head-to-head study evaluating SKYRIZI ® (risankizumab) versus STELARA ® (ustekinumab) in moderate to severe Crohn's disease will be presented – Analyses on clinical and ...

With a new chief at the helm and higher profit projections in sight, AbbVie is entering a “new chapter," CEO Robert Michael told analysts Thursday. During the second quarter, AbbVie reported a 29.8% ...

A European Commission committee is recommending AbbVie's Rinvoq for treatment of giant cell arteritis following Phase 3 clinical trial results that showed efficacy and safety in the inflammatory ...

AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...